BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 34266395)

  • 1. Proton-pump inhibitor vs. H2-receptor blocker use and overall risk of CKD progression.
    Cholin L; Ashour T; Mehdi A; Taliercio JJ; Daou R; Arrigain S; Schold JD; Thomas G; Nally J; Nakhoul NL; Nakhoul GN
    BMC Nephrol; 2021 Jul; 22(1):264. PubMed ID: 34266395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term kidney outcomes among users of proton pump inhibitors without intervening acute kidney injury.
    Xie Y; Bowe B; Li T; Xian H; Yan Y; Al-Aly Z
    Kidney Int; 2017 Jun; 91(6):1482-1494. PubMed ID: 28237709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proton Pump Inhibitors and Risk of Incident CKD and Progression to ESRD.
    Xie Y; Bowe B; Li T; Xian H; Balasubramanian S; Al-Aly Z
    J Am Soc Nephrol; 2016 Oct; 27(10):3153-3163. PubMed ID: 27080976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proton Pump Inhibitor Use and the Risk of Chronic Kidney Disease.
    Lazarus B; Chen Y; Wilson FP; Sang Y; Chang AR; Coresh J; Grams ME
    JAMA Intern Med; 2016 Feb; 176(2):238-46. PubMed ID: 26752337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-indicated initiation of proton pump inhibitor and risk of adverse outcomes in patients with underlying chronic kidney disease: a nationwide, retrospective, cohort study.
    Kim SG; Cho JM; Han K; Joo KW; Lee S; Kim Y; Cho S; Huh H; Kim M; Kang E; Kim DK; Park S
    BMJ Open; 2024 Jan; 14(1):e078032. PubMed ID: 38286693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association Between Proton Pump Inhibitor Use and Risk of Progression of Chronic Kidney Disease.
    Klatte DCF; Gasparini A; Xu H; de Deco P; Trevisan M; Johansson ALV; Wettermark B; Ärnlöv J; Janmaat CJ; Lindholm B; Dekker FW; Coresh J; Grams ME; Carrero JJ
    Gastroenterology; 2017 Sep; 153(3):702-710. PubMed ID: 28583827
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Associations of Proton-Pump Inhibitors and H2 Receptor Antagonists with Chronic Kidney Disease: A Meta-Analysis.
    Wijarnpreecha K; Thongprayoon C; Chesdachai S; Panjawatanana P; Ungprasert P; Cheungpasitporn W
    Dig Dis Sci; 2017 Oct; 62(10):2821-2827. PubMed ID: 28836158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of Progression of Nonalbuminuric CKD to End-Stage Kidney Disease in People With Diabetes: The CRIC (Chronic Renal Insufficiency Cohort) Study.
    Koye DN; Magliano DJ; Reid CM; Jepson C; Feldman HI; Herman WH; Shaw JE
    Am J Kidney Dis; 2018 Nov; 72(5):653-661. PubMed ID: 29784612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proton Pump Inhibitors, Histamine-2 Receptor Antagonists, and Hip Fracture Risk among Patients on Hemodialysis.
    Vangala C; Niu J; Lenihan CR; Mitch WE; Navaneethan SD; Winkelmayer WC
    Clin J Am Soc Nephrol; 2018 Oct; 13(10):1534-1541. PubMed ID: 30262672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proton pump inhibitors and chronic kidney disease risk: a comparative study with histamine-2 receptor antagonists.
    Kweon T; Kim Y; Lee KJ; Seo WW; Seo SI; Shin WG; Shin DH
    Sci Rep; 2023 Dec; 13(1):21169. PubMed ID: 38036592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adverse outcomes of proton pump inhibitors in patients with chronic kidney disease: The CKD-REIN cohort study.
    Liabeuf S; Lambert O; Metzger M; Hamroun A; Laville M; Laville SM; Frimat L; Pecoits-Filho R; Fouque D; Massy ZA; Jacquelinet C; Stengel B;
    Br J Clin Pharmacol; 2021 Jul; 87(7):2967-2976. PubMed ID: 33368448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proton pump inhibitor use and progression to major adverse renal events: a competing risk analysis.
    Grant CH; Gillis KA; Lees JS; Traynor JP; Mark PB; Stevens KI
    QJM; 2019 Nov; 112(11):835-840. PubMed ID: 31251364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histamine H2-Blocker and Proton Pump Inhibitor Use and the Risk of Pneumonia in Acute Stroke: A Retrospective Analysis on Susceptible Patients.
    Arai N; Nakamizo T; Ihara H; Koide T; Nakamura A; Tabuse M; Miyazaki H
    PLoS One; 2017; 12(1):e0169300. PubMed ID: 28085910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proton Pump Inhibitors and Risk of Acute and Chronic Kidney Disease: A Retrospective Cohort Study.
    Hart E; Dunn TE; Feuerstein S; Jacobs DM
    Pharmacotherapy; 2019 Apr; 39(4):443-453. PubMed ID: 30779194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of death among users of Proton Pump Inhibitors: a longitudinal observational cohort study of United States veterans.
    Xie Y; Bowe B; Li T; Xian H; Yan Y; Al-Aly Z
    BMJ Open; 2017 Jul; 7(6):e015735. PubMed ID: 28676480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retrospective analysis of the effect of acid-suppressant therapy on clinicopathologic parameters of cats with chronic kidney disease.
    Gould E; Klos J; Price J; Harris T; Vaden S; Tolbert MK
    J Feline Med Surg; 2018 Jun; 20(6):520-527. PubMed ID: 28703633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progression to end-stage kidney disease in Japanese children with chronic kidney disease: results of a nationwide prospective cohort study.
    Ishikura K; Uemura O; Hamasaki Y; Ito S; Wada N; Hattori M; Ohashi Y; Tanaka R; Nakanishi K; Kaneko T; Honda M; ;
    Nephrol Dial Transplant; 2014 Apr; 29(4):878-84. PubMed ID: 24516225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Effect of Proton Pump Inhibitor Use on the Course of Kidney Function in Patients with Chronic Kidney Disease Stages G3a to G4.
    Giusti S; Lin Y; Sogbetun F; Nakhoul N; Liu S; Shi L; Batuman V
    Am J Med Sci; 2021 Nov; 362(5):453-461. PubMed ID: 34033809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is Chronic Kidney Disease Progression Influenced by the Type of Renin-Angiotensin-System Blocker Used?
    Silvariño R; Rios P; Baldovinos G; Chichet MA; Perg N; Sola L; Saona G; De Souza N; Lamadrid V; Gadola L
    Nephron; 2019; 143(2):100-107. PubMed ID: 31203280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Associations between Proton Pump Inhibitor and Histamine-2 Receptor Antagonist and Bone Mineral Density among Kidney Transplant Recipients.
    Lyu B; Hansen KE; Jorgenson MR; Astor BC
    Am J Nephrol; 2020; 51(6):433-441. PubMed ID: 32485707
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.